Darryl Kato, Regina Wai-Yan Choy, Eda Canales, Ryan A Dick, April D Lake, Nathan D Shapiro, Elbert Chin, Jiayao Li, Jennifer R Zhang, Qiaoyin Wu, Roland D Saito, Sammy Metobo, Evangelos Aktoudianakis, Scott D Schroeder, Zheng-Yu Yang, Dylan M Glatt, Scott Balsitis, Lindsay Gamelin, Mei Yu, Guofeng Cheng, William E Delaney, John O Link
Chronic hepatitis B (CHB) virus infection afflicts hundreds of millions of people and causes nearly one million deaths annually. The high levels of circulating viral surface antigen (HBsAg) that characterize CHB may lead to T-cell exhaustion, resulting in an impaired antiviral immune response in the host. Agents that suppress HBsAg could help invigorate immunity toward infected hepatocytes and facilitate a functional cure. A series of dihydropyridoisoquinolizinone (DHQ) inhibitors of human poly(A) polymerases PAPD5/7 were reported to suppress HBsAg in vitro...
April 11, 2024: ACS Medicinal Chemistry Letters